Study I1F-MC-RHBV (RHBV) is a Phase 3, multicenter, randomized, double-blind, active- and placebo-controlled, parallel-group, outpatient study examining the efficacy and safety of 2 treatment regimens of ixekizumab, 80 mg Q2W and 80 mg Q4Wsubcutaneous (SC), as compared to placebo SC in patients with rad-axSpA, during a 16-week